Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world safety study of apatinib mesylate tablets
ChiCTR1900024531Phase 4Recruiting
- Sponsor
- Chinese Academy of Medical Sciences & Peking Union Medical College
- Start
- Sep 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in cancer, sponsored by Chinese Academy of Medical Sciences & Peking Union Medical College. Primary endpoint: Adverse reactions. Started Sep 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
cancer
Beyond the preview
Go deeper on ChiCTR1900024531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024531.